Is Crinetics Pharmaceuticals, Inc. (CRNX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 25.7% / 30% | 0.0% / 30% | 675.53% / 5% | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 25.7% / 33% | 0.0% / 33% | 675.53% / 5% | ✗ NOT HALAL |
| MSCI | 4.3% / 33% | 91.3% / 33% | 0.1% / 33% | 675.53% / 5% | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 25.7% / 33% | 0.0% / 33% | 675.53% / 5% | ✗ NOT HALAL |
| FTSE | 4.3% / 33% | 91.3% / 33% | 0.1% / 50% | 675.53% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -2169.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -40.2% | |
| Return on Assets (ROA) | -25.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$378M |
| Free Cash Flow | -$384M |
| Total Debt | $49M |
| Debt-to-Equity | 4.9 |
| Current Ratio | 12.3 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $36.31 |
| 50-Day MA | $43.76 |
| 200-Day MA | $39.74 |
| Avg Volume | 1.2M |
| Beta | 0.2 |
|
52-Week Range
$24.10
| |
About Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Crinetics Pharmaceuticals, Inc. (CRNX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Crinetics Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Crinetics Pharmaceuticals, Inc.'s debt ratio?
Crinetics Pharmaceuticals, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.3%.
What are Crinetics Pharmaceuticals, Inc.'s key financial metrics?
Crinetics Pharmaceuticals, Inc. has a market capitalization of $3.5B, and revenue of $8M. Return on equity stands at -40.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.